Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'KNI-272' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 19 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Matsumoto, H; Matsuda, T; Nakata, S; Mitoguchi, T; Kimura, T; Hayashi, Y; Kiso, Y
      Synthesis and biological evaluation of prodrug-type anti-HIV agents: Esterconjugates of carboxylic acid-containing dipeptide HIV protease inhibitorsand a reverse transcriptase inhibitor

      BIOORGANIC & MEDICINAL CHEMISTRY
    2. Velazquez-Campoy, A; Luque, I; Todd, MJ; Milutinovich, M; Kiso, Y; Freire, E
      Thermodynamic dissection of the binding energetics of KNT-272, a potent HIV-1 protease inhibitor

      PROTEIN SCIENCE
    3. Mardis, K; Luo, R; David, L; Potter, M; Glemza, A; Payne, G; Gilson, MK
      Modeling molecular recognition: Theory and application

      JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
    4. Mimoto, T; Hattori, N; Takaku, H; Kisanuki, S; Fukazawa, T; Terashima, K; Kato, R; Nojima, S; Misawa, S; Ueno, T; Imai, J; Enomoto, H; Tanaka, S; Sakikawa, H; Shintani, M; Hayashi, H; Kiso, Y
      Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere

      CHEMICAL & PHARMACEUTICAL BULLETIN
    5. Hawkins, V; Shen, Q; Chiueh, CC
      Kynostatin and 17 beta-estradiol prevent the apoptotic death of human neuroblastoma cells exposed to HIV-1 protease

      JOURNAL OF BIOMEDICAL SCIENCE
    6. Humphrey, RW; Wyvill, KM; Nguyen, BY; Shay, LE; Kohler, DR; Steinberg, SM; Ueno, T; Fukasawa, T; Shintani, M; Hayashi, H; Mitsuya, H; Yarchoan, R
      A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection

      ANTIVIRAL RESEARCH
    7. Kiriyama, A; Nishiura, T; Yamaji, H; Takada, K
      Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor

      BIOPHARMACEUTICS & DRUG DISPOSITION
    8. Mimoto, T; Kato, R; Takaku, H; Nojima, S; Terashima, K; Misawa, S; Fukazawa, T; Ueno, T; Sato, H; Shintani, M; Kiso, Y; Hayashi, H
      Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine

      JOURNAL OF MEDICINAL CHEMISTRY
    9. Kiso, Y; Matsumoto, H; Mizumoto, S; Kimura, T; Fujiwara, Y; Akaji, K
      Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic

      BIOPOLYMERS
    10. Katoh, E; Yamazaki, T; Kiso, Y; Wingfield, PT; Stahl, SJ; Kaufman, JD; Torchia, DA
      Determination of the rate of monomer interchange in a ligand-bound homodimeric protein from NOESY cross peaks: Application to the HIV protease/KNI-529 complex

      JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
    11. KISO Y; YAMAGUCHI S; MATSUMOTO H; MIMOTO T; KATO R; NOJIMA S; TAKAKU H; FUKAZAWA T; KIMURA T; AKAJI K
      KNI-577, A POTENT SMALL-SIZED HIV PROTEAS E INHIBITOR BASED ON THE DIPEPTIDE CONTAINING THE HYDROXYMETHYLCARBONYL ISOSTERE AS AN IDEAL TRANSITION-STATE MIMIC

      Archiv der pharmazie
    12. Kiso, Y
      Design and synthesis of a covalently linked HIV-1 protease dimer analog and peptidomimetic inhibitors

      JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN
    13. MURCKO MA; RAO BG; GOMPERTS R
      CONFORMATIONAL-ANALYSIS OF HIV-1 PROTEASE INHIBITORS .2. THIOPROLINE P'(1) RESIDUE IN THE POTENT INHIBITOR KNI-272

      Journal of computational chemistry
    14. KIRIYAMA A; NISHIURA T; ISHINO M; YAMAMOTO Y; OGITA I; KISO Y; TAKADA K
      BINDING CHARACTERISTICS OF KNI-272 TO PLASMA-PROTEINS, A NEW POTENT TRIPEPTIDE HIV PROTEASE INHIBITOR

      Biopharmaceutics & drug disposition
    15. KIRIYAMA A; SUGAHARA M; YOSHIKAWA Y; KISO Y; TAKADA K
      THE BIOAVAILABILITY OF ORAL DOSAGE FORMS OF A NEW HIV-1 PROTEASE INHIBITOR, KNI-272, IN BEAGLE DOGS

      Biopharmaceutics & drug disposition
    16. BALDWIN ET; BHAT TN; GULNIK S; LIU BS; TOPOL IA; KISO Y; MIMOTO T; MITSUYA H; ERICKSON JW
      STRUCTURE OF HIV-1 PROTEASE WITH KNI-272, A TIGHT-BINDING TRANSITION-STATE ANALOG CONTAINING ALLOPHENYLNORSTATINE

      Structure
    17. SUGAHARA M; KIRIYAMA A; HAMADA Y; KISO Y; TAKADA K
      ABSORPTION OF NEW HIV-1 PROTEASE INHIBITOR, KNI-272, AFTER INTRADUODENAL AND INTRAGASTRIC ADMINISTRATIONS TO RATS - EFFECT OF SOLVENT

      Biopharmaceutics & drug disposition
    18. KIRIYAMA A; FUJITA K; TAKEMURA S; KURAMOTO H; KISO Y; TAKADA K
      PLASMA PHARMACOKINETICS AND URINARY AND BILIARY-EXCRETION OF A NEW POTENT TRIPEPTIDE HIV-1 PROTEASE INHIBITOR, KNI-272, IN RATS AFTER INTRAVENOUS ADMINISTRATION

      Biopharmaceutics & drug disposition
    19. KIRIYAMA A; MIMOTO T; KISANUKI S; KISO Y; TAKADA K
      COMPARISON OF A NEW ORALLY POTENT TRIPEPTIDE HIV-1 PROTEASE INHIBITOR(ANTI-AIDS DRUG) BASED ON PHARMACOKINETIC CHARACTERISTICS IN RATS AFTER INTRAVENOUS AND INTRADUODENAL ADMINISTRATIONS

      Biopharmaceutics & drug disposition


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/01/21 alle ore 17:58:19